Otezla (Wave 2) | LaunchTrends | US | 2014
This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the syndicated report will assess physician perceptions at one month, six months and one year after the launch of Apremilast. The reports will further explore where Apremilast is being placed in the treatment algorithm and in which patient types, strengths and weaknesses of the product profile compared to other agents, and the overall impact of the launch on the market landscape.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
